Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$119.07 - $145.42 $2.04 Million - $2.49 Million
17,100 Added 76.0%
39,600 $4.72 Million
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $650,363 - $778,623
-5,300 Reduced 19.06%
22,500 $3.21 Million
Q1 2024

May 15, 2024

SELL
$102.11 - $135.92 $4.57 Million - $6.09 Million
-44,800 Reduced 61.71%
27,800 $3.57 Million
Q4 2023

Feb 14, 2024

BUY
$87.78 - $105.45 $5.5 Million - $6.6 Million
62,600 Added 626.0%
72,600 $7.51 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $782,084 - $1.72 Million
8,600 Added 614.29%
10,000 $909,000
Q2 2023

Aug 14, 2023

BUY
$155.98 - $172.65 $218,372 - $241,710
1,400 New
1,400 $226,000
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $343,008 - $420,948
3,600 Added 144.0%
6,100 $608,000
Q2 2022

Aug 15, 2022

SELL
$103.24 - $121.81 $154,860 - $182,715
-1,500 Reduced 37.5%
2,500 $279,000
Q4 2021

Feb 14, 2022

BUY
$95.88 - $117.08 $383,520 - $468,320
4,000 New
4,000 $448,000
Q1 2021

May 17, 2021

SELL
$67.06 - $75.82 $234,710 - $265,370
-3,500 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$63.89 - $73.8 $223,615 - $258,300
3,500 New
3,500 $244,000
Q1 2020

May 15, 2020

SELL
$49.46 - $64.78 $385,788 - $505,284
-7,800 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$49.86 - $58.26 $388,908 - $454,428
7,800 New
7,800 $451,000
Q4 2018

Feb 14, 2019

SELL
$41.54 - $47.25 $299,088 - $340,200
-7,200 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$46.76 - $51.24 $32,732 - $35,868
700 Added 10.77%
7,200 $339,000
Q2 2018

Aug 14, 2018

SELL
$44.29 - $50.42 $172,731 - $196,638
-3,900 Reduced 37.5%
6,500 $300,000
Q1 2018

May 15, 2018

BUY
$48.49 - $58.14 $150,319 - $180,234
3,100 Added 42.47%
10,400 $512,000
Q4 2017

Feb 14, 2018

BUY
$47.53 - $53.73 $346,969 - $392,229
7,300
7,300 $392,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.